Adial Pharmaceuticals, Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 274,139 shares of common stock, representing 4.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power over these shares under an Investment Management Agreement. The filing is a joint statement dated May 15, 2026.
Positive
None.
Negative
None.
Insights
Armistice Capital reports a sub-5% shared holding with voting authority.
The filing states 274,139 shares are beneficially owned with shared voting and dispositive power, reflecting manager-level control via an Investment Management Agreement rather than direct sole control. Ownership is reported at 4.99% of the class as of the filing.
Monitor subsequent amendments or Schedule 13D filings for changes in percentage or voting arrangements; this disclosure indicates managerial voting influence through the Master Fund relationship as of May 15, 2026.
Key Figures
Shares beneficially owned:274,139 sharesPercent of class:4.99%Filing date:May 15, 2026+3 more
6 metrics
Shares beneficially owned274,139 sharesAmount reported as beneficially owned
Percent of class4.99%Percent of common stock reported
Filing dateMay 15, 2026Date of joint Schedule 13G/A signature
CUSIP00688A304Identifier for Adial common stock
Shared voting power274,139 sharesShared power to vote as stated in Item 4(c)(ii)
Shared dispositive power274,139 sharesShared power to dispose as stated in Item 4(c)(iv)
Key Terms
Schedule 13G/A, Beneficial ownership, Investment Management Agreement, Shared dispositive power
4 terms
Schedule 13G/Aregulatory
"Joint statement reporting beneficial ownership and amendments"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficial ownershipfinancial
"Amount beneficially owned: 274,139 (b) Percent of class: 4.99%"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Investment Management Agreementlegal
"Armistice Capital exercises voting and investment power under an Investment Management Agreement"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
Shared dispositive powercorporate
"Shared power to dispose or to direct the disposition of: 274,139"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Adial Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00688A304
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00688A304
1
Names of Reporting Persons
Armistice Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
274,139.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
274,139.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
274,139.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.99 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
CUSIP Number(s):
00688A304
1
Names of Reporting Persons
Steven Boyd
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
274,139.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
274,139.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
274,139.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.99 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Adial Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
4870 Sadler Road, Ste 300, Glen Allen, VA 23060
Item 2.
(a)
Name of person filing:
Armistice Capital, LLC
Steven Boyd
Collectively, the "Reporting Persons"
(b)
Address or principal business office or, if none, residence:
Armistice Capital, LLC
510 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
Steven Boyd
c/o Armistice Capital, LLC
510 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
(c)
Citizenship:
Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
00688A304
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
274,139
(b)
Percent of class:
4.99%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
274,139
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
274,139
Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund
Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management
Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer
held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held
by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to
beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically
disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to
vote or dispose of such securities as a result of its Investment Management Agreement with Armistice
Capital.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Armistice Capital, LLC
Signature:
/s/ Steven Boyd
Name/Title:
Steven Boyd - Managing Member
Date:
05/15/2026
Steven Boyd
Signature:
/s/ Steven Boyd
Name/Title:
Steven Boyd
Date:
05/15/2026
Exhibit Information
JOINT FILING STATEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
Dated: May 15, 2026
Armistice Capital, LLC
By: /s/ Steven Boyd
Steven Boyd - Managing Member
Steven Boyd
By: /s/ Steven Boyd
What stake did Armistice Capital report in Adial (ADIL)?
Armistice Capital and Steven Boyd reported beneficial ownership of 274,139 shares, equal to 4.99% of Adial's common stock, per the joint Schedule 13G/A filed May 15, 2026.
Who holds voting and disposition power for the reported ADIL shares?
The filing states shared voting and shared dispositive power over 274,139 shares is exercised by Armistice Capital under an Investment Management Agreement with the Master Fund.
Does the Schedule 13G/A state Armistice owns the shares directly?
No; the Master Fund is the direct holder and Armistice Capital is the investment manager exercising voting and investment power under an Investment Management Agreement, per the filing.
What date and signature appear on the filing for ADIL?
The joint statement is dated May 15, 2026 and is signed by Steven Boyd as Managing Member of Armistice Capital, LLC, per the Schedule 13G/A.
